Skip to content
Life Sciences Series B Founded 2016

Avrobio

Developer of gene therapies to treat genetic diseases. The company uses a proprietary Plato platform to develop lentiviral gene therapies for lysosomal disorders. The product pipeline includes AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 Hunter syndrome. The company was founded in 2016 and headquartered in Cambridge, United States. It has raised $85.5M in series b funding, with backing from…

📍 Cambridge, United States · Genomics,

Funding snapshot

Last roundSeries B
Amount$60M
Date1 February 2018
Total raised$85M
Team size1

About

Developer of gene therapies to treat genetic diseases. The company uses a proprietary Plato platform to develop lentiviral gene therapies for lysosomal disorders. The product pipeline includes AVR-RD-02 for Gaucher disease, AVR-RD-04 for cystinosis, and AVR-RD-05 Hunter syndrome. The company was founded in 2016 and headquartered in Cambridge, United States. It has raised $85.5M in series b funding, with backing from Citadel, Brace Pharma Capital, Eventide Funds, Atlas Venture, and others. The company operates in the Life Sciences - Genomics, Life Sciences - Gene Therapy, Life Sciences - Rare Diseases space. The company leverages advanced technology to deliver innovative solutions tailored to its target market, addressing key industry challenges and driving value for its customers.

Business model

Rare Diseases > Drugs > Metabolic Disorders > Lysosomal Diseases,

Genomics > Applied Genomics > Clinical Genomics > Therapeutics

Institutional investors

Citadel Brace Pharma Capital Eventide Funds Atlas Venture SV Health Investors Blackstone Morningside Aisling Capital Cormorant Asset Management JLABS

Latest coverage

No articles yet.

Raising like Avrobio?

Analyze your pitch deck before your next raise.

Analyze My Deck →